Myelodysplastic syndromes

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, James M. Foran, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J Maness-Harris, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Mark A. Schroeder, Paul J. Shami, Richard M. Stone, James E. Thompson & 1 others Peter Westervelt

Research output: Contribution to journalReview article

135 Citations (Scopus)

Abstract

These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Four drugs have recently been approved by the FDA for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic abnormalities; azacytidine and decitabine for treating patients with higher-risk or nonresponsive MDS; and deferasirox for iron chelation of iron overloaded patients with MDS. However, because a substantial proportion of patient subsets with MDS lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important.116,119,120,128,129 Progress toward improving management of MDS has occurred over the past few years, and more advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.

Original languageEnglish (US)
Pages (from-to)30-56
Number of pages27
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Myelodysplastic Syndromes
decitabine
Iron
Clinical Trials
Azacitidine
Therapeutic Uses
Disease Management
Natural History
Practice Guidelines
Chromosome Aberrations
Thrombocytopenia
Quality of Life
Guidelines
Cytokines
Therapeutics
Pharmaceutical Preparations

Keywords

  • Chronic myelomonocytic leukemia
  • Cytopenias
  • Myelodysplastic syndromes
  • NCCN clinical practice guidelines
  • NCCN guidelines
  • Refractory anemia
  • Treatment

ASJC Scopus subject areas

  • Oncology

Cite this

Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., ... Westervelt, P. (2011). Myelodysplastic syndromes. JNCCN Journal of the National Comprehensive Cancer Network, 9(1), 30-56. https://doi.org/10.6004/jnccn.2011.0005

Myelodysplastic syndromes. / Greenberg, Peter L.; Attar, Eyal; Bennett, John M.; Bloomfield, Clara D.; De Castro, Carlos M.; Deeg, H. Joachim; Foran, James M.; Gaensler, Karin; Garcia-Manero, Guillermo; Gore, Steven D.; Head, David; Komrokji, Rami; Maness-Harris, Lori J; Millenson, Michael; Nimer, Stephen D.; O'Donnell, Margaret R.; Schroeder, Mark A.; Shami, Paul J.; Stone, Richard M.; Thompson, James E.; Westervelt, Peter.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 9, No. 1, 01.01.2011, p. 30-56.

Research output: Contribution to journalReview article

Greenberg, PL, Attar, E, Bennett, JM, Bloomfield, CD, De Castro, CM, Deeg, HJ, Foran, JM, Gaensler, K, Garcia-Manero, G, Gore, SD, Head, D, Komrokji, R, Maness-Harris, LJ, Millenson, M, Nimer, SD, O'Donnell, MR, Schroeder, MA, Shami, PJ, Stone, RM, Thompson, JE & Westervelt, P 2011, 'Myelodysplastic syndromes', JNCCN Journal of the National Comprehensive Cancer Network, vol. 9, no. 1, pp. 30-56. https://doi.org/10.6004/jnccn.2011.0005
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ et al. Myelodysplastic syndromes. JNCCN Journal of the National Comprehensive Cancer Network. 2011 Jan 1;9(1):30-56. https://doi.org/10.6004/jnccn.2011.0005
Greenberg, Peter L. ; Attar, Eyal ; Bennett, John M. ; Bloomfield, Clara D. ; De Castro, Carlos M. ; Deeg, H. Joachim ; Foran, James M. ; Gaensler, Karin ; Garcia-Manero, Guillermo ; Gore, Steven D. ; Head, David ; Komrokji, Rami ; Maness-Harris, Lori J ; Millenson, Michael ; Nimer, Stephen D. ; O'Donnell, Margaret R. ; Schroeder, Mark A. ; Shami, Paul J. ; Stone, Richard M. ; Thompson, James E. ; Westervelt, Peter. / Myelodysplastic syndromes. In: JNCCN Journal of the National Comprehensive Cancer Network. 2011 ; Vol. 9, No. 1. pp. 30-56.
@article{534c856b06154cfda085b7745ca5730c,
title = "Myelodysplastic syndromes",
abstract = "These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Four drugs have recently been approved by the FDA for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic abnormalities; azacytidine and decitabine for treating patients with higher-risk or nonresponsive MDS; and deferasirox for iron chelation of iron overloaded patients with MDS. However, because a substantial proportion of patient subsets with MDS lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important.116,119,120,128,129 Progress toward improving management of MDS has occurred over the past few years, and more advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.",
keywords = "Chronic myelomonocytic leukemia, Cytopenias, Myelodysplastic syndromes, NCCN clinical practice guidelines, NCCN guidelines, Refractory anemia, Treatment",
author = "Greenberg, {Peter L.} and Eyal Attar and Bennett, {John M.} and Bloomfield, {Clara D.} and {De Castro}, {Carlos M.} and Deeg, {H. Joachim} and Foran, {James M.} and Karin Gaensler and Guillermo Garcia-Manero and Gore, {Steven D.} and David Head and Rami Komrokji and Maness-Harris, {Lori J} and Michael Millenson and Nimer, {Stephen D.} and O'Donnell, {Margaret R.} and Schroeder, {Mark A.} and Shami, {Paul J.} and Stone, {Richard M.} and Thompson, {James E.} and Peter Westervelt",
year = "2011",
month = "1",
day = "1",
doi = "10.6004/jnccn.2011.0005",
language = "English (US)",
volume = "9",
pages = "30--56",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "1",

}

TY - JOUR

T1 - Myelodysplastic syndromes

AU - Greenberg, Peter L.

AU - Attar, Eyal

AU - Bennett, John M.

AU - Bloomfield, Clara D.

AU - De Castro, Carlos M.

AU - Deeg, H. Joachim

AU - Foran, James M.

AU - Gaensler, Karin

AU - Garcia-Manero, Guillermo

AU - Gore, Steven D.

AU - Head, David

AU - Komrokji, Rami

AU - Maness-Harris, Lori J

AU - Millenson, Michael

AU - Nimer, Stephen D.

AU - O'Donnell, Margaret R.

AU - Schroeder, Mark A.

AU - Shami, Paul J.

AU - Stone, Richard M.

AU - Thompson, James E.

AU - Westervelt, Peter

PY - 2011/1/1

Y1 - 2011/1/1

N2 - These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Four drugs have recently been approved by the FDA for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic abnormalities; azacytidine and decitabine for treating patients with higher-risk or nonresponsive MDS; and deferasirox for iron chelation of iron overloaded patients with MDS. However, because a substantial proportion of patient subsets with MDS lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important.116,119,120,128,129 Progress toward improving management of MDS has occurred over the past few years, and more advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.

AB - These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Four drugs have recently been approved by the FDA for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic abnormalities; azacytidine and decitabine for treating patients with higher-risk or nonresponsive MDS; and deferasirox for iron chelation of iron overloaded patients with MDS. However, because a substantial proportion of patient subsets with MDS lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important.116,119,120,128,129 Progress toward improving management of MDS has occurred over the past few years, and more advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.

KW - Chronic myelomonocytic leukemia

KW - Cytopenias

KW - Myelodysplastic syndromes

KW - NCCN clinical practice guidelines

KW - NCCN guidelines

KW - Refractory anemia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=78951487923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78951487923&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2011.0005

DO - 10.6004/jnccn.2011.0005

M3 - Review article

VL - 9

SP - 30

EP - 56

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 1

ER -